Dublin, May 13, 2024 (GLOBE NEWSWIRE) -- The "MRSA Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.
Global MRSA Drugs Market to Reach $1.6 Billion by 2030
The global market for MRSA Drugs estimated at US$1.2 Billion in the year 2023, is projected to reach a revised size of US$1.6 Billion by 2030, growing at a CAGR of 4.4% over the analysis period 2023-2030. Glycopeptides & Lipoglycopeptides Drug Class, one of the segments analyzed in the report, is expected to record a 4.5% CAGR and reach US$660.2 Million by the end of the analysis period. Growth in the Lipopeptides Drug Class segment is estimated at 4.9% CAGR for the next 7-year period. 
The U.S. Market is Estimated at $357.9 Million, While China is Forecast to Grow at 4.2% CAGR
The MRSA Drugs market in the U.S. is estimated at US$357.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$283.5 Million by the year 2030 trailing a CAGR of 4.2% over the analysis period 2023 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.1% and 3.7% respectively over the 2023-2030 period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 183 |
| Forecast Period | 2023 - 2030 |
| Estimated Market Value (USD) in 2023 | $1.2 Billion |
| Forecasted Market Value (USD) by 2030 | $1.6 Billion |
| Compound Annual Growth Rate | 4.4% |
| Regions Covered | Global |
MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- MRSA Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
- Global Economic Update
FOCUS ON SELECT PLAYERS
- Absynth Biologics
- Allergan PLC
- AmpliPhi Biosciences Corporation
- AstraZeneca PLC
- Basilea Pharmaceutica Ltd.
- Baxter International, Inc.
- Cempra, Inc.
- CrystalGenomics Inc.
- Debiopharm Group
- Galapagos NV
- GlaxoSmithKline plc
- Innovation Pharmaceuticals Inc.
- Kyorin Pharmaceutical Co., Ltd.
- Lytix Biopharma AS
- Melinta Therapeutics, Inc.
- Merck & Co., Inc.
- Nabriva Therapeutics US, Inc.
- NovaDigm Therapeutics, Inc.
- Paratek Pharmaceuticals, Inc.
- Pfizer, Inc.
- R-Pharm-US LLC
- Savara Inc.
- Sealife PHARMA GMBH
- Sequella, Inc.
- The Medicines Company
- Theravance Biopharma, Inc.
- XBiotech Inc.
For more information about this report visit https://www.researchandmarkets.com/r/ip16ic
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
